Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
dilanubicel (DVX101)
i
Other names:
DVX101, NLA101 , NLA 101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Deverra Therapeutics
Drug class:
Immunomodulator
Related drugs:
‹
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
CMP-001 (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
CY-101 (0)
rimiducid activated rivogenlecleucel (0)
coprelotamab (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
SI-101 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
hydroxychloroquine (7)
quaratusugene ozeplasmid (3)
CMP-001 (3)
Orca-T (1)
SQZ-AAC-HPV (1)
SV-102 (1)
MAM-06.301 (1)
ABV-1501 (0)
ALT-801 (0)
ATA520 (0)
HLA-matched donor mononuclear enriched leukocytes (0)
BMS-986242 (0)
CEP-37250 (0)
CK0801 (0)
CO-1002 (0)
CY-101 (0)
rimiducid activated rivogenlecleucel (0)
coprelotamab (0)
GSK2302024A (0)
Ganfule (0)
IL-17E (0)
IMCnyeso (0)
KFA115 (0)
MVA-BN-HER2 (0)
NOV-002 (0)
nelipepimut-S (0)
ORB-011 (0)
engineered donor allograft cell therapy (0)
parvovirus H-1 (0)
FT1050+FT4145 programmed mPB (0)
allodepleted T-cell immunotherapeutics (0)
SER-401 (0)
SI-101 (0)
ScTIL (0)
ScTIL210 (0)
TAEK-VAC-HerBy vaccine (0)
TAK-012 (0)
TST010 (0)
Undisclosed CISH inactivated TIL (0)
alpha-tocopheroloxyacetic acid (0)
WTX212 (0)
SB-313 (0)
thymalfasin (0)
BAZE-X1 (0)
chlorogenic acid (0)
dendritic cell activation therapy (0)
hV01 (0)
minocycline (0)
EC-18 (0)
HF1K16 (0)
oral rhLF (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCI-2017-02205) (NCT03399773)
Phase 2
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Recruiting
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
02/15/2024
Initiation :
05/10/2022
Primary completion :
10/08/2024
Completion :
06/30/2026
HLA-DRB1 • CD34 • HLA-B
|
cyclophosphamide • fludarabine IV • thiotepa • Omisirge (omidubicel) • cyclophosphamide intravenous • dilanubicel (DVX101)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login